Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSA5 Protocol for Pediatric and Adolescent NHL
NCT00002691Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 1995
- Primary completion
- Jun 2000
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asparaginase escherichia coli, cyclophosphamide, cytarabine, daunorubicin, dexamethasone and 3 more in non-Hodgkin lymphoma (NHL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Feasibility of treating all histologic subgroups on one protocol. Started Aug 1995; status: completed.
02
Drugs
asparaginase escherichia colicyclophosphamidecytarabinedaunorubicindexamethasone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002691.